Clearmind Medicine reports three published US patent applications
The applications pair LSD, ketamine and ibogaine with N-acylethanolamines, while the scope of any patent rights remains undecided.
Theo Marchetti
Three drug-combination patent applications have been published in the United States, according to a Sept. 23 issuer release. Clearmind Medicine Inc. NASDAQCMND said the 3 applications concern LSD, ketamine and ibogaine paired with N-acylethanolamines, including palmitoylethanolamide, or PEA.
Clearmind shares were quoted at US$0.82 on NASDAQCMND at 2:36 p.m. EDT on Sept. 24. The NASDAQCMND quote showed a 3.28 per cent daily decline at 2:36 p.m. EDT on Sept. 24. The issuer's disclosure supplied no date for a patent office decision on the three applications.
Publication makes the proposed inventions public, but does not mean the patent office has allowed the claims or granted a patent. The U.S. Patent and Trademark Office's patent guide says examiners may reject claims in light of earlier work. It says applications generally publish 18 months after the earliest effective filing or priority date.
Clearmind did not provide those dates or the applications' publication numbers in its announcement, so the announcement does not establish when any of the three applications was originally submitted. The 18-month period is a general rule, not a filing date that can be assigned to these particular applications. The release did not report an examiner's decision on any of them.
Patent Scope Remains Undecided
The Sept. 23 release describes depression, post-traumatic stress disorder, pain and substance use disorders as potential uses for the combinations. It reports no trial phase, patient count, endpoint, comparative dose or safety result for those combinations. Clearmind did not report an FDA authorization or a clinical result for these combinations in its Sept. 23 release.
The release refers to compounds paired with N-acylethanolamines, a group that includes PEA. Clearmind also referred to an earlier published application for MDMA paired with N-acylethanolamines, aimed at potential use in PTSD, anxiety and eating disorders. The Sept. 23 disclosure concerns the other three substances, and its release does not reproduce the proposed patent claims for any of the new applications.
Read more: Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial
Clearmind said on Sept. 23 that its broader portfolio comprised 19 patent families and 32 granted patents. Those portfolio totals include existing intellectual property and do not show that the three newly announced applications have been granted. The release did not break down the status of each new application beyond saying it was published.
"The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company."
Clearmind made that caution in its Sept. 23 release.
Clearmind gave no timetable in its Sept. 23 disclosure for the patent office's next action on the three published applications. That action, whether an allowance or a rejection of claims, will determine what the company must do next.
